Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa (dabigatran) is now licensed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Pradaxa is the first new treatment option for anticoagulation in atrial fibrillation | SCIENCE PHOTO LIBRARY
Pradaxa is the first new treatment option for anticoagulation in atrial fibrillation | SCIENCE PHOTO LIBRARY

Pradaxa (dabigatran) can now be considered for the prevention of stroke and systemic  embolism in at-risk patients with atrial fibrillation (AF), as an alternative to warfarin. Unlike warfarin, no loading dose is required with dabigatran, nor regular blood tests to monitor INR.  However, the monitoring of dabigatran-related anticoagulation may be helpful to prevent dabigatran overexposure in the presence of additional risk factors eg, ≥75 years, renal impairment or low body weight.

In the non-inferiority RE-LY study, 18113 patients with AF and risk factors for stroke were randomised and allocated to receive either dabigatran, blinded and using fixed doses of 110mg or 150mg twice daily, or open-label warfarin, adjusted according to INR. Rate of stroke or systemic embolism was used as the primary efficacy measure. Additionally, the rate of major bleed was identified as a measure of safety and defined as a ≥20g/litre reduction in haemoglobin level, transfusion of ≥2 units of blood, or symptomatic bleeding in a critical area or organ. The median duration of follow up was 2.0 years.

Results found dabigatran to be non-inferior to warfarin in reducing the rate of stroke or systemic embolism at the lower dose and displayed superior efficacy at the higher dose (rate per year: warfarin 1.71%; low dose dabigatran 1.54%; high dose dabigatran 1.11% [95% CI; p<0.001 for non-inferiority and superiority, respectively]).

The rates of major bleed were comparable between the warfarin and high dose dabigatran groups (relative risk 0.93 [95% CI; p<0.32]) but significantly lower when comparing the warfarin and low dose dabigatran group (relative risk 0.80 [95% CI; p<0.003]).

Only Pradaxa 110mg and 150mg capsules are licensed for this new indication.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases